<xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:g="http://xbrl.dcca.dk/sob" xmlns:b="http://xbrl.dcca.dk/entryBalanceSheetAccountFormIncomeStatementByNature" xmlns:h="http://xbrl.dcca.dk/mrv" xmlns:f="http://xbrl.dcca.dk/arr" xmlns:d="http://xbrl.dcca.dk/cmn" xmlns:e="http://xbrl.dcca.dk/fsa" xmlns:c="http://xbrl.dcca.dk/gsd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://xbrl.dcca.dk/entryBalanceSheetAccountFormIncomeStatementByNature http://archprod.service.eogs.dk/taxonomy/20231001/entryDanishGAAPBalanceSheetAccountFormIncomeStatementByNatureIncludingManagementsReviewStatisticsAndTax20231001.xsd"><link:schemaRef xlink:type="simple" xlink:href="http://archprod.service.eogs.dk/taxonomy/20231001/entryDanishGAAPBalanceSheetAccountFormIncomeStatementByNatureIncludingManagementsReviewStatisticsAndTax20231001.xsd"/><c:InformationOnTypeOfSubmittedReport contextRef="c1">Årsrapport</c:InformationOnTypeOfSubmittedReport><c:IdentificationNumberCvrOfSubmittingEnterprise contextRef="c1">25492145</c:IdentificationNumberCvrOfSubmittingEnterprise><c:NameOfSubmittingEnterprise contextRef="c1">RSM Danmark, Statsautoriseret Revisionspartnerselskab</c:NameOfSubmittingEnterprise><c:AddressOfSubmittingEnterpriseStreetAndNumber contextRef="c1">Kingosvej, 3</c:AddressOfSubmittingEnterpriseStreetAndNumber><c:AddressOfSubmittingEnterprisePostcodeAndTown contextRef="c1">2630, Taastrup</c:AddressOfSubmittingEnterprisePostcodeAndTown><c:PrecedingReportingPeriodStartDate contextRef="c1">2023-01-01</c:PrecedingReportingPeriodStartDate><c:PredingReportingPeriodEndDate contextRef="c1">2023-12-31</c:PredingReportingPeriodEndDate><c:ReportingPeriodStartDate contextRef="c1">2024-01-01</c:ReportingPeriodStartDate><c:ReportingPeriodEndDate contextRef="c1">2024-12-31</c:ReportingPeriodEndDate><c:IdentificationNumberCvrOfReportingEntity contextRef="c1">32558011</c:IdentificationNumberCvrOfReportingEntity><c:NameOfReportingEntity contextRef="c1">MedEngine DK ApS</c:NameOfReportingEntity><c:AddressOfReportingEntityStreetName contextRef="c1">Klosterstræde</c:AddressOfReportingEntityStreetName><c:AddressOfReportingEntityStreetBuildingIdentifier contextRef="c1">23.3</c:AddressOfReportingEntityStreetBuildingIdentifier><c:AddressOfReportingEntityPostCodeIdentifier contextRef="c1">1157</c:AddressOfReportingEntityPostCodeIdentifier><c:AddressOfReportingEntityDistrictName contextRef="c1">København K</c:AddressOfReportingEntityDistrictName><c:DateOfFoundationOfReportingEntity contextRef="c1">2009-10-01</c:DateOfFoundationOfReportingEntity><c:RegisteredOfficeOfReportingEntity contextRef="c1">København</c:RegisteredOfficeOfReportingEntity><d:NameOfAuditFirm contextRef="c37">RSM Danmark, Statsautoriseret Revisionspartnerselskab</d:NameOfAuditFirm><d:IdentificationNumberCvrOfAuditFirm contextRef="c37">25492145</d:IdentificationNumberCvrOfAuditFirm><d:NameAndSurnameOfAuditor contextRef="c37">Frederik Bille</d:NameAndSurnameOfAuditor><d:DescriptionOfAuditor contextRef="c37">statsautoriseret revisor</d:DescriptionOfAuditor><d:IdentificationNumberOfAuditor contextRef="c37">mne33208</d:IdentificationNumberOfAuditor><c:AddressOfAuditorStreetName contextRef="c37">Kingosvej</c:AddressOfAuditorStreetName><c:AddressOfAuditorStreetBuildingIdentifier contextRef="c37">3</c:AddressOfAuditorStreetBuildingIdentifier><c:AddressOfAuditorPostCodeIdentifier contextRef="c37">2630</c:AddressOfAuditorPostCodeIdentifier><c:AddressOfAuditorDistrictName contextRef="c37">Taastrup</c:AddressOfAuditorDistrictName><c:AddressOfAuditorCountry contextRef="c37">Danmark</c:AddressOfAuditorCountry><c:TelephoneNumberOfAuditor contextRef="c37">+45 43 99 92 92</c:TelephoneNumberOfAuditor><c:EmailOfAuditor contextRef="c1">taastrup@rsm.dk</c:EmailOfAuditor><c:DateOfGeneralMeeting contextRef="c1">2025-03-27</c:DateOfGeneralMeeting><c:NameAndSurnameOfChairmanOfGeneralMeeting contextRef="c1">Tero Markus Ylisaukko-oja</c:NameAndSurnameOfChairmanOfGeneralMeeting><e:ClassOfReportingEntity contextRef="c1">Regnskabsklasse B</e:ClassOfReportingEntity><d:TypeOfAuditorAssistance contextRef="c1">Revisionspåtegning</d:TypeOfAuditorAssistance><c:ToolForPreparingTheXBRLInstanceDocument contextRef="c1">CaseWare fra Revisorgruppen Danmark</c:ToolForPreparingTheXBRLInstanceDocument><f:AddresseeOfAuditorsReportOnAuditedFinancialStatements contextRef="c1">anpartshaverne</f:AddresseeOfAuditorsReportOnAuditedFinancialStatements><f:SignatureOfAuditorsPlace contextRef="c1">Taastrup</f:SignatureOfAuditorsPlace><f:SignatureOfAuditorsDate contextRef="c1">2025-03-27</f:SignatureOfAuditorsDate><g:PlaceOfSignatureOfStatement contextRef="c1">Copenhagen</g:PlaceOfSignatureOfStatement><g:DateOfApprovalOfAnnualReport contextRef="c1">2025-03-27</g:DateOfApprovalOfAnnualReport><f:TypeOfBasisForModifiedOpinionOnAuditedFinancialStatements contextRef="c1">Grundlag for konklusion</f:TypeOfBasisForModifiedOpinionOnAuditedFinancialStatements><f:TypeOfModifiedOpinionOnAuditedFinancialStatements contextRef="c1">Konklusion</f:TypeOfModifiedOpinionOnAuditedFinancialStatements><e:GrossProfitLoss contextRef="c1" unitRef="u5" decimals="0">2286080</e:GrossProfitLoss><e:GrossProfitLoss contextRef="c2" unitRef="u5" decimals="0">1758681</e:GrossProfitLoss><e:EmployeeBenefitsExpense contextRef="c1" unitRef="u5" decimals="0">1174682</e:EmployeeBenefitsExpense><e:EmployeeBenefitsExpense contextRef="c2" unitRef="u5" decimals="0">2560871</e:EmployeeBenefitsExpense><e:DepreciationAmortisationExpenseAndImpairmentLossesOfPropertyPlantAndEquipmentAndIntangibleAssetsRecognisedInProfitOrLoss contextRef="c1" unitRef="u5" decimals="0">78598</e:DepreciationAmortisationExpenseAndImpairmentLossesOfPropertyPlantAndEquipmentAndIntangibleAssetsRecognisedInProfitOrLoss><e:DepreciationAmortisationExpenseAndImpairmentLossesOfPropertyPlantAndEquipmentAndIntangibleAssetsRecognisedInProfitOrLoss contextRef="c2" unitRef="u5" decimals="0">78598</e:DepreciationAmortisationExpenseAndImpairmentLossesOfPropertyPlantAndEquipmentAndIntangibleAssetsRecognisedInProfitOrLoss><e:ProfitLossFromOrdinaryOperatingActivities contextRef="c1" unitRef="u5" decimals="0">1032800</e:ProfitLossFromOrdinaryOperatingActivities><e:ProfitLossFromOrdinaryOperatingActivities contextRef="c2" unitRef="u5" decimals="0">-880788</e:ProfitLossFromOrdinaryOperatingActivities><e:OtherFinanceIncome contextRef="c1" unitRef="u5" decimals="0">10662</e:OtherFinanceIncome><e:OtherFinanceIncome contextRef="c2" unitRef="u5" decimals="0">12482</e:OtherFinanceIncome><e:OtherFinanceExpenses contextRef="c1" unitRef="u5" decimals="0">23036</e:OtherFinanceExpenses><e:OtherFinanceExpenses contextRef="c2" unitRef="u5" decimals="0">14962</e:OtherFinanceExpenses><e:ProfitLossFromOrdinaryActivitiesBeforeTax contextRef="c1" unitRef="u5" decimals="0">1020426</e:ProfitLossFromOrdinaryActivitiesBeforeTax><e:ProfitLossFromOrdinaryActivitiesBeforeTax contextRef="c2" unitRef="u5" decimals="0">-883268</e:ProfitLossFromOrdinaryActivitiesBeforeTax><e:TaxExpense contextRef="c1" unitRef="u5" decimals="0">0</e:TaxExpense><e:TaxExpense contextRef="c2" unitRef="u5" decimals="0">-66066</e:TaxExpense><e:ProfitLoss contextRef="c1" unitRef="u5" decimals="0">1020426</e:ProfitLoss><e:ProfitLoss contextRef="c2" unitRef="u5" decimals="0">-817202</e:ProfitLoss><e:TransferredToFromRetainedEarnings contextRef="c1" unitRef="u5" decimals="0">1020426</e:TransferredToFromRetainedEarnings><e:TransferredToFromRetainedEarnings contextRef="c2" unitRef="u5" decimals="0">-817202</e:TransferredToFromRetainedEarnings><e:FixturesFittingsToolsAndEquipment contextRef="c4" unitRef="u5" decimals="0">45264</e:FixturesFittingsToolsAndEquipment><e:FixturesFittingsToolsAndEquipment contextRef="c3" unitRef="u5" decimals="0">123862</e:FixturesFittingsToolsAndEquipment><e:PropertyPlantAndEquipment contextRef="c4" unitRef="u5" decimals="0">45264</e:PropertyPlantAndEquipment><e:PropertyPlantAndEquipment contextRef="c3" unitRef="u5" decimals="0">123862</e:PropertyPlantAndEquipment><e:NoncurrentAssets contextRef="c4" unitRef="u5" decimals="0">45264</e:NoncurrentAssets><e:NoncurrentAssets contextRef="c3" unitRef="u5" decimals="0">123862</e:NoncurrentAssets><e:ShorttermTradeReceivables contextRef="c4" unitRef="u5" decimals="0">3132100</e:ShorttermTradeReceivables><e:ShorttermTradeReceivables contextRef="c3" unitRef="u5" decimals="0">1583251</e:ShorttermTradeReceivables><e:ShorttermReceivablesFromGroupEnterprises contextRef="c4" unitRef="u5" decimals="0">24864</e:ShorttermReceivablesFromGroupEnterprises><e:ShorttermReceivablesFromGroupEnterprises contextRef="c3" unitRef="u5" decimals="0">0</e:ShorttermReceivablesFromGroupEnterprises><e:ShorttermTaxReceivablesFromGroupEnterprises contextRef="c4" unitRef="u5" decimals="0">0</e:ShorttermTaxReceivablesFromGroupEnterprises><e:ShorttermTaxReceivablesFromGroupEnterprises contextRef="c3" unitRef="u5" decimals="0">24864</e:ShorttermTaxReceivablesFromGroupEnterprises><e:OtherShorttermReceivables contextRef="c4" unitRef="u5" decimals="0">159451</e:OtherShorttermReceivables><e:OtherShorttermReceivables contextRef="c3" unitRef="u5" decimals="0">282653</e:OtherShorttermReceivables><e:DeferredIncomeAssets contextRef="c4" unitRef="u5" decimals="0">97918</e:DeferredIncomeAssets><e:DeferredIncomeAssets contextRef="c3" unitRef="u5" decimals="0">88968</e:DeferredIncomeAssets><e:ShorttermReceivables contextRef="c4" unitRef="u5" decimals="0">3414333</e:ShorttermReceivables><e:ShorttermReceivables contextRef="c3" unitRef="u5" decimals="0">1979736</e:ShorttermReceivables><e:CashAndCashEquivalents contextRef="c4" unitRef="u5" decimals="0">551769</e:CashAndCashEquivalents><e:CashAndCashEquivalents contextRef="c3" unitRef="u5" decimals="0">1426838</e:CashAndCashEquivalents><e:CurrentAssets contextRef="c4" unitRef="u5" decimals="0">3966102</e:CurrentAssets><e:CurrentAssets contextRef="c3" unitRef="u5" decimals="0">3406574</e:CurrentAssets><e:Assets contextRef="c4" unitRef="u5" decimals="0">4011366</e:Assets><e:Assets contextRef="c3" unitRef="u5" decimals="0">3530436</e:Assets><e:RecognisedButNotOwnedAssets contextRef="c1" unitRef="u5" decimals="0">0</e:RecognisedButNotOwnedAssets><e:ContributedCapital contextRef="c4" unitRef="u5" decimals="0">126000</e:ContributedCapital><e:ContributedCapital contextRef="c3" unitRef="u5" decimals="0">126000</e:ContributedCapital><e:RetainedEarnings contextRef="c4" unitRef="u5" decimals="0">835829</e:RetainedEarnings><e:RetainedEarnings contextRef="c3" unitRef="u5" decimals="0">-184597</e:RetainedEarnings><e:Equity contextRef="c4" unitRef="u5" decimals="0">961829</e:Equity><e:Equity contextRef="c3" unitRef="u5" decimals="0">-58597</e:Equity><e:ShorttermTradePayables contextRef="c4" unitRef="u5" decimals="0">413060</e:ShorttermTradePayables><e:ShorttermTradePayables contextRef="c3" unitRef="u5" decimals="0">827249</e:ShorttermTradePayables><e:ShorttermPayablesToGroupEnterprises contextRef="c4" unitRef="u5" decimals="0">2216041</e:ShorttermPayablesToGroupEnterprises><e:ShorttermPayablesToGroupEnterprises contextRef="c3" unitRef="u5" decimals="0">2531193</e:ShorttermPayablesToGroupEnterprises><e:OtherPayablesIncludingTaxPayablesLiabilitiesOtherThanProvisionsShortterm contextRef="c4" unitRef="u5" decimals="0">152060</e:OtherPayablesIncludingTaxPayablesLiabilitiesOtherThanProvisionsShortterm><e:OtherPayablesIncludingTaxPayablesLiabilitiesOtherThanProvisionsShortterm contextRef="c3" unitRef="u5" decimals="0">230591</e:OtherPayablesIncludingTaxPayablesLiabilitiesOtherThanProvisionsShortterm><e:ShorttermDeferredIncome contextRef="c4" unitRef="u5" decimals="0">268376</e:ShorttermDeferredIncome><e:ShorttermDeferredIncome contextRef="c3" unitRef="u5" decimals="0">0</e:ShorttermDeferredIncome><e:ShorttermLiabilitiesOtherThanProvisions contextRef="c4" unitRef="u5" decimals="0">3049537</e:ShorttermLiabilitiesOtherThanProvisions><e:ShorttermLiabilitiesOtherThanProvisions contextRef="c3" unitRef="u5" decimals="0">3589033</e:ShorttermLiabilitiesOtherThanProvisions><e:LiabilitiesOtherThanProvisions contextRef="c4" unitRef="u5" decimals="0">3049537</e:LiabilitiesOtherThanProvisions><e:LiabilitiesOtherThanProvisions contextRef="c3" unitRef="u5" decimals="0">3589033</e:LiabilitiesOtherThanProvisions><e:LiabilitiesAndEquity contextRef="c4" unitRef="u5" decimals="0">4011366</e:LiabilitiesAndEquity><e:LiabilitiesAndEquity contextRef="c3" unitRef="u5" decimals="0">3530436</e:LiabilitiesAndEquity><e:WagesAndSalaries contextRef="c1" unitRef="u5" decimals="0">999196</e:WagesAndSalaries><e:WagesAndSalaries contextRef="c2" unitRef="u5" decimals="0">2231319</e:WagesAndSalaries><e:PostemploymentBenefitExpense contextRef="c1" unitRef="u5" decimals="0">145959</e:PostemploymentBenefitExpense><e:PostemploymentBenefitExpense contextRef="c2" unitRef="u5" decimals="0">286896</e:PostemploymentBenefitExpense><e:SocialSecurityContributions contextRef="c1" unitRef="u5" decimals="0">29527</e:SocialSecurityContributions><e:SocialSecurityContributions contextRef="c2" unitRef="u5" decimals="0">42656</e:SocialSecurityContributions><e:EmployeeBenefitsExpense contextRef="c1" unitRef="u5" decimals="0">1174682</e:EmployeeBenefitsExpense><e:EmployeeBenefitsExpense contextRef="c2" unitRef="u5" decimals="0">2560871</e:EmployeeBenefitsExpense><e:AverageNumberOfEmployees contextRef="c1" unitRef="u7" decimals="INF">3</e:AverageNumberOfEmployees><e:AverageNumberOfEmployees contextRef="c2" unitRef="u7" decimals="INF">5</e:AverageNumberOfEmployees><e:PropertyPlantAndEquipmentGross contextRef="c99" unitRef="u5" decimals="0">235795</e:PropertyPlantAndEquipmentGross><e:PropertyPlantAndEquipmentGross contextRef="c101" unitRef="u5" decimals="0">235795</e:PropertyPlantAndEquipmentGross><e:AccumulatedImpairmentLossesAndDepreciationOfPropertyPlantAndEquipment contextRef="c99" unitRef="u5" decimals="0">111933</e:AccumulatedImpairmentLossesAndDepreciationOfPropertyPlantAndEquipment><e:DepreciationOfPropertyPlantAndEquipment contextRef="c100" unitRef="u5" decimals="0">78598</e:DepreciationOfPropertyPlantAndEquipment><e:AccumulatedImpairmentLossesAndDepreciationOfPropertyPlantAndEquipment contextRef="c101" unitRef="u5" decimals="0">190531</e:AccumulatedImpairmentLossesAndDepreciationOfPropertyPlantAndEquipment><e:PropertyPlantAndEquipment contextRef="c101" unitRef="u5" decimals="0">45264</e:PropertyPlantAndEquipment><e:Equity contextRef="c119" unitRef="u5" decimals="0">126000</e:Equity><e:Equity contextRef="c478" unitRef="u5" decimals="0">126000</e:Equity><e:Equity contextRef="c121" unitRef="u5" decimals="0">126000</e:Equity><e:Equity contextRef="c480" unitRef="u5" decimals="0">126000</e:Equity><e:Equity contextRef="c137" unitRef="u5" decimals="0">-184597</e:Equity><e:Equity contextRef="c498" unitRef="u5" decimals="0">632605</e:Equity><e:ProfitLoss contextRef="c138" unitRef="u5" decimals="0">1020426</e:ProfitLoss><e:ProfitLoss contextRef="c499" unitRef="u5" decimals="0">-817202</e:ProfitLoss><e:Equity contextRef="c139" unitRef="u5" decimals="0">835829</e:Equity><e:Equity contextRef="c500" unitRef="u5" decimals="0">-184597</e:Equity><g:IdentificationOfApprovedAnnualReport contextRef="c1" xml:lang="en">Today, the Managing Director has approved the annual report of MedEngine DK ApS for the financial year 1 January - 31 December 2024.
</g:IdentificationOfApprovedAnnualReport><g:ConfirmationThatAnnualReportIsPresentedInAccordanceWithRequirementsProvidedForByLegislationAnyStandardsAndRequirementsProvidedByArticlesOfAssociationOrByAgreement contextRef="c1" xml:lang="en">The annual report has been prepared in accordance with the Danish Financial Statements Act.
</g:ConfirmationThatAnnualReportIsPresentedInAccordanceWithRequirementsProvidedForByLegislationAnyStandardsAndRequirementsProvidedByArticlesOfAssociationOrByAgreement><g:ConfirmationThatFinancialStatementGivesTrueAndFairViewOfAssetsLiabilitiesEquityFinancialPositionAndResults contextRef="c1" xml:lang="en">I consider the chosen accounting policy to be appropriate, and in my opinion, the financial statements give a true and fair view of the financial position of the Company at 31 December 2024 and of the results of the Company's operations for the financial year 1 January – 31 December 2024.
</g:ConfirmationThatFinancialStatementGivesTrueAndFairViewOfAssetsLiabilitiesEquityFinancialPositionAndResults><g:ManagementsStatementAboutManagementsReview contextRef="c1" xml:lang="en">Further, in my opinion, the Management's review gives a true and fair review of the matters discussed in the Management's review.
</g:ManagementsStatementAboutManagementsReview><g:RecommendationForApprovalOfAnnualReportByGeneralMeeting contextRef="c1" xml:lang="en">We recommend that the annual report be approved at the Annual General Meeting.
</g:RecommendationForApprovalOfAnnualReportByGeneralMeeting><d:NameAndSurnameOfMemberOfExecutiveBoard contextRef="c29">Tero Markus Ylisaukko-oja</d:NameAndSurnameOfMemberOfExecutiveBoard><f:OpinionOnAuditedFinancialStatements contextRef="c1" xml:lang="en">We have audited the financial statements of MedEngine DK ApS for the financial year 1 January - 31 December 2024, which comprise a summary of significant accounting policies, income statement, balance sheet, statement of changes in equity and notes, for the Company. The financial statements are prepared under the Danish Financial Statements Act.

In our opinion, the financial statements give a true and fair view of the financial position of the Company at 31 December 2024, and of the results of the Company's operations for the financial year 1 January - 31 December 2024 in accordance with the Danish Financial Statements Act.
</f:OpinionOnAuditedFinancialStatements><f:DescriptionOfQualificationsOfAuditedFinancialStatements contextRef="c1" xml:lang="en">Basis for conclusion
We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the “Auditor’s Responsibilities for the Audit of the Financial Statements” section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountants’ International Code of Ethics for Professional Accountants (IESBA Code) and the additional ethical requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the IESBA Code. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.
</f:DescriptionOfQualificationsOfAuditedFinancialStatements><f:StatementOfExecutiveAndSupervisoryBoardsResponsibilityForFinancialStatements contextRef="c1" xml:lang="en">Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as Management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, Management is responsible for assessing the Company’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting in preparing the financial statements unless Management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.
</f:StatementOfExecutiveAndSupervisoryBoardsResponsibilityForFinancialStatements><f:StatementOfAuditorsResponsibilityForAuditAndAuditPerformed contextRef="c1" xml:lang="en">Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control.

Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by Management.

Conclude on the appropriateness of Management’s use of the going concern basis of accounting in preparing the financial statements and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company’s ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor’s report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor’s report. However, future events or conditions may cause the Company to cease to continue as a going concern.

Evaluate the overall presentation, structure and contents of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that gives a true and fair view.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.
</f:StatementOfAuditorsResponsibilityForAuditAndAuditPerformed><f:StatementOnManagementsReviewAuditorsReportOnAuditedFinancialStatements contextRef="c1" xml:lang="en">Statement on Management’s Review
Management is responsible for Management’s Review.

Our opinion on the financial statements does not cover Management’s Review, and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read Management’s Review and, in doing so, consider whether Management’s Review is materially inconsistent with the financial statements or our knowledge obtained during the audit, or otherwise appears to be materially misstated.

Moreover, it is our responsibility to consider whether Management’s Review provides the information required under the Danish Financial Statements Act.

Based on the work we have performed, we conclude that Management’s Review is in accordance with the financial statements and has been prepared in accordance with the requirements of the Danish Financial Statement Act. We did not identify any material misstatement of Management’s Review.
</f:StatementOnManagementsReviewAuditorsReportOnAuditedFinancialStatements><h:DescriptionOfPrimaryActivitiesOfEntity contextRef="c1" xml:lang="en">Description of key activities of the company
The company provides specialized services to the pharmaceutical industry, including market access, real-world evidence research, and scientific content services.
</h:DescriptionOfPrimaryActivitiesOfEntity><h:DescriptionOfDevelopmentInActivitiesAndFinancialAffairs contextRef="c1" xml:lang="en">Significant changes in the company's activities and financial matters
The gross profit for the year totals DKK 2.286.080 against DKK 1.758.681 last year. Income or loss from ordinary activities after tax totals DKK 1.020.426 against DKK -817.202 last year. 

In 2024, the company’s cash and cash equivalents decreased by DKK 0,0875.069, i.e. from DKK 0,01.426.838 to DKK 0,0551.769.
</h:DescriptionOfDevelopmentInActivitiesAndFinancialAffairs><e:InformationOnReportingClassOfEntity contextRef="c1" xml:lang="en">The annual report for MedEngine DK ApS has been presented in accordance with the Danish Financial Statements Act regulations concerning reporting class B enterprises. Furthermore, the company has decided to comply with certain rules applying to reporting class C enterprises.

The accounting policies are unchanged from last year, and the annual report is presented in DKK.
</e:InformationOnReportingClassOfEntity><e:DescriptionOfGeneralMattersRelatedToRecognitionMeasurementAndChangesInAccountingPolicies contextRef="c1" xml:lang="en">Recognition and measurement in general
Income is recognised in the income statement concurrently with its realisation, including the recognition of value adjustments of financial assets and liabilities. Likewise, all costs are recognised in the income statement, including depreciations amortisations, write-downs for impairment, provisions, and reversals due to changes in estimated amounts previously recognised in the income statement.

Assets are recognised in the statement of financial position when it seems probable that future economic benefits will flow to the company and the value of the asset can be reliably measured.

Liabilities are recognised in the statement of financial position when it is seems probable that future economic benefits will flow out of the company and the value of the liability can be reliably measured.

Assets and liabilities are measured at cost at the initial recognition. Hereafter, assets and liabilities are measured as described below for each individual accounting item.

Certain financial assets and liabilities are measured at amortised cost, allowing a constant effective interest rate to be recognised during the useful life of the asset or liability. Amortised cost is recognised as the original cost less any payments, plus/less accrued amortisations of the difference between cost and nominal amount. In this way, capital losses and gains are allocated over the useful life of the liability.

Upon recognition and measurement, allowances are made for such predictable losses and risks which may arise prior to the presentation of the annual report and concern matters that exist on the reporting date.
</e:DescriptionOfGeneralMattersRelatedToRecognitionMeasurementAndChangesInAccountingPolicies><e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfRevenue contextRef="c1" xml:lang="en">Gross profit
In pursuance of section 32 of the Danish Financial Statement Act. the company does not disclose its revenue. 

Gross fit reflects an aggregation of revenue less direct costs and other external expenses. 

Revenue
Revenue is measured at the fiar of the agreed consideration, excluding VAT and other indirect taxes. Revenue is net of all types of discounts granted. 

Income from the sale of services is recognised in the income statement, provided that the transfer of risk, usually on delivery to the buyer, has taken place and that the income can be measured reliably and is expected to be received. 
</e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfRevenue><e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfCostOfSales contextRef="c1" xml:lang="en">Direct costinclude the costs used in generating the year´s revenue. 
</e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfCostOfSales><e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfExternalExpenses contextRef="c1" xml:lang="en">Other external expenses comprise expenses incurred for distribution, sales, advertising, administration, premises, loss on receivables, and operational leasing costs.
</e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfExternalExpenses><e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfEmployeeBenefitExpense contextRef="c1" xml:lang="en">Staff costs
Staff costs include salaries and wages, including holiday allowances, pensions, and other social security costs, etc., for staff members.
</e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfEmployeeBenefitExpense><e:DescriptionOfMethodsOfImpairmentLossesAndDepreciation contextRef="c1" xml:lang="en">Depreciation, amortisation, and write-down for impairment
Depreciation, amortisation, and write-down for impairment comprise depreciation on, amortisation of, and write-down for impairment of intangible and tangible assets, respectively.
</e:DescriptionOfMethodsOfImpairmentLossesAndDepreciation><e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfFinanceIncomeAndExpenses contextRef="c1" xml:lang="en">Financial income and expenses
Financial income and expenses are recognised in the income statement with the amounts concerning the financial year. Financial income and expenses comprise interest income and expenses.
</e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfFinanceIncomeAndExpenses><e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfTaxExpenses contextRef="c1" xml:lang="en">Tax on net profit or loss for the year
Tax for the year comprises the current income tax for the year and changes in deferred tax and is recognised in the income statement with the share attributable to the net profit or loss for the year and directly in equity with the share attributable to entries directly in equity. 

The company is subject to Danish rules on compulsory joint taxation of Danish group enterprises.

The current Danish income tax is allocated among the jointly taxed companies proportional to their respective taxable income (full allocation with reimbursement of tax losses).
</e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfTaxExpenses><e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfPropertyPlantAndEquipment contextRef="c1" xml:lang="en">Equipment
Equipment are measured at cost less accrued depreciation and write-down for impairment.

The depreciable amount is cost less any expected residual value after the end of the useful life of the asset. The amortisation period and the residual value are determined at the acquisition date and reassessed annually. If the residual value exceeds the carrying amount, the depreciation is discontinued.

The cost comprises acquisition cost and costs directly associated with the acquisition until the time when the asset is ready for use.

Depreciation is done on a straight-line basis according to an assessment of the expected useful life and the residual value of the individual assets:

Other fixtures and fittings, tools and equipment Useful life 3 years Residual value 0%
Minor assets with an expected useful life of less than 1 year are recognised as costs in the income statement in the year of acquisition.
</e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfPropertyPlantAndEquipment><e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfReceivables contextRef="c1" xml:lang="en">Receivables
Receivables are measured at amortised cost.

Impairment losses are calculated as the difference between the carrying amount of accounts receivable and the present value of the expected cash flows, including the realisable value of any securities received. The effective interest rate for the individual account receivable or portfolio is used as the discount rate.
</e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfReceivables><e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfDeferredIncomeAssets contextRef="c1" xml:lang="en">Prepayments
Prepayments recognised under assets comprise incurred costs concerning the following financial year.
</e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfDeferredIncomeAssets><e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfCashAndCashEquivalents contextRef="c1" xml:lang="en">Cash and cash equivalents
Cash and cash equivalents comprise cash at bank.
</e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfCashAndCashEquivalents><e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfTaxPayablesAndDeferredTax contextRef="c1" xml:lang="en">Income tax and deferred tax
Current tax liabilities and current tax receivable are recognised in the statement of financial position as calculated tax on the taxable income for the year, adjusted for tax of previous years' taxable income and for tax paid on account.

The company is jointly taxed with consolidated Danish companies. The current corporate income tax is distributed between the jointly taxed companies in proportion to their taxable income and with full distribution with reimbursement as to tax losses. The jointly taxed companies are comprised by the Danish tax prepayment scheme.

Joint taxation contributions payable and receivable are recognised in the statement of financial position as ”Tax receivables from group enterprises" or "Income tax payable to group enterprises"

Deferred tax is measured on the basis of temporary differences in assets and liabilities with a focus on the statement of financial position. Deferred tax is measured at net realisable value.

Deferred tax assets, including the tax value of tax losses allowed for carryforward, are recognised at the value at which they are expected to be realisable, either by settlement against tax of future earnings or by set-off in deferred tax liabilities within the same legal tax unit. Any deferred net tax assets are measured at net realisable value.
</e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfTaxPayablesAndDeferredTax><e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfLiabilitiesOtherThanProvisions contextRef="c1" xml:lang="en">Liabilities other than provisions
Liabilities are measured at amortised cost which usually corresponds to the nominal value.
</e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfLiabilitiesOtherThanProvisions><e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfDeferredIncomeLiabilities contextRef="c1" xml:lang="en">Deferred income
Payments received concerning future income are recognised under deferred income.
</e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfDeferredIncomeLiabilities><e:DisclosureOfContingentLiabilities contextRef="c1" xml:lang="en">3. Contingencies
Contingent liabilities

DKK in thousands
Total contingent liabilities
232


Joint taxation
With IWA CONSULTING ApS, company reg. no 21857890 as administration company, the company is subject to the Danish scheme of joint taxation and unlimitedly, jointly, and severally liable, along with the other jointly taxed companies, for the total corporation tax.

The company is unlimitedly, jointly, and severally liable, along with the other jointly taxed companies, for any obligations to withhold tax on interest, royalties, and dividends.

</e:DisclosureOfContingentLiabilities><!--Aktuelle periode enkelt selskab--><context id="c1"><entity><identifier scheme="http://www.dcca.dk/cvr">32558011</identifier></entity><period><startDate>2024-01-01</startDate><endDate>2024-12-31</endDate></period></context><!--Forrige periode enkelt selskab--><context id="c2"><entity><identifier scheme="http://www.dcca.dk/cvr">32558011</identifier></entity><period><startDate>2023-01-01</startDate><endDate>2023-12-31</endDate></period></context><!--Slutdato forrige periode enkelt selskab--><context id="c3"><entity><identifier scheme="http://www.dcca.dk/cvr">32558011</identifier></entity><period><instant>2023-12-31</instant></period></context><!--Slutdato aktuelle periode enkelt selskab--><context id="c4"><entity><identifier scheme="http://www.dcca.dk/cvr">32558011</identifier></entity><period><instant>2024-12-31</instant></period></context><!--CEO1--><context id="c29"><entity><identifier scheme="http://www.dcca.dk/cvr">32558011</identifier></entity><period><startDate>2024-01-01</startDate><endDate>2024-12-31</endDate></period><scenario><xbrldi:typedMember dimension="d:IdentificationOfMemberOfExecutiveBoardDimension"><d:memberOfBoardIdentifier>1</d:memberOfBoardIdentifier></xbrldi:typedMember></scenario></context><!--REVISOR1--><context id="c37"><entity><identifier scheme="http://www.dcca.dk/cvr">32558011</identifier></entity><period><startDate>2024-01-01</startDate><endDate>2024-12-31</endDate></period><scenario><xbrldi:typedMember dimension="d:IdentificationOfAuditorDimension"><d:auditorIdentifier>1</d:auditorIdentifier></xbrldi:typedMember></scenario></context><!--Andre anlag aktuel primo--><context id="c99"><entity><identifier scheme="http://www.dcca.dk/cvr">32558011</identifier></entity><period><instant>2024-01-01</instant></period><scenario><xbrldi:explicitMember dimension="e:ClassesOfPropertyPlantAndEquipmentDimension">e:FixturesFittingsToolsAndEquipmentMember</xbrldi:explicitMember></scenario></context><!--Andre anlag aktuel i aaret--><context id="c100"><entity><identifier scheme="http://www.dcca.dk/cvr">32558011</identifier></entity><period><startDate>2024-01-01</startDate><endDate>2024-12-31</endDate></period><scenario><xbrldi:explicitMember dimension="e:ClassesOfPropertyPlantAndEquipmentDimension">e:FixturesFittingsToolsAndEquipmentMember</xbrldi:explicitMember></scenario></context><!--Andre anlag aktuel ultimo--><context id="c101"><entity><identifier scheme="http://www.dcca.dk/cvr">32558011</identifier></entity><period><instant>2024-12-31</instant></period><scenario><xbrldi:explicitMember dimension="e:ClassesOfPropertyPlantAndEquipmentDimension">e:FixturesFittingsToolsAndEquipmentMember</xbrldi:explicitMember></scenario></context><!--Virksomhedskapital aktuel primo--><context id="c119"><entity><identifier scheme="http://www.dcca.dk/cvr">32558011</identifier></entity><period><instant>2024-01-01</instant></period><scenario><xbrldi:explicitMember dimension="e:ClassesOfEquityDimension">e:ContributedCapitalMember</xbrldi:explicitMember></scenario></context><!--Virksomhedskapital aktuel ultimo--><context id="c121"><entity><identifier scheme="http://www.dcca.dk/cvr">32558011</identifier></entity><period><instant>2024-12-31</instant></period><scenario><xbrldi:explicitMember dimension="e:ClassesOfEquityDimension">e:ContributedCapitalMember</xbrldi:explicitMember></scenario></context><!--Overfort res aktuel primo--><context id="c137"><entity><identifier scheme="http://www.dcca.dk/cvr">32558011</identifier></entity><period><instant>2024-01-01</instant></period><scenario><xbrldi:explicitMember dimension="e:ClassesOfEquityDimension">e:RetainedEarningsMember</xbrldi:explicitMember></scenario></context><!--Overfort res aktuel i aaret--><context id="c138"><entity><identifier scheme="http://www.dcca.dk/cvr">32558011</identifier></entity><period><startDate>2024-01-01</startDate><endDate>2024-12-31</endDate></period><scenario><xbrldi:explicitMember dimension="e:ClassesOfEquityDimension">e:RetainedEarningsMember</xbrldi:explicitMember></scenario></context><!--Overfort res aktuel ultimo--><context id="c139"><entity><identifier scheme="http://www.dcca.dk/cvr">32558011</identifier></entity><period><instant>2024-12-31</instant></period><scenario><xbrldi:explicitMember dimension="e:ClassesOfEquityDimension">e:RetainedEarningsMember</xbrldi:explicitMember></scenario></context><!--Virksomhedskapital forrige EKprimo--><context id="c478"><entity><identifier scheme="http://www.dcca.dk/cvr">32558011</identifier></entity><period><instant>2023-01-01</instant></period><scenario><xbrldi:explicitMember dimension="e:ClassesOfEquityDimension">e:ContributedCapitalMember</xbrldi:explicitMember></scenario></context><!--Virksomhedskapital forrige EKultimo--><context id="c480"><entity><identifier scheme="http://www.dcca.dk/cvr">32558011</identifier></entity><period><instant>2023-12-31</instant></period><scenario><xbrldi:explicitMember dimension="e:ClassesOfEquityDimension">e:ContributedCapitalMember</xbrldi:explicitMember></scenario></context><!--Overfort res forrige EKprimo--><context id="c498"><entity><identifier scheme="http://www.dcca.dk/cvr">32558011</identifier></entity><period><instant>2023-01-01</instant></period><scenario><xbrldi:explicitMember dimension="e:ClassesOfEquityDimension">e:RetainedEarningsMember</xbrldi:explicitMember></scenario></context><!--Overfort res forrige EKi aaret--><context id="c499"><entity><identifier scheme="http://www.dcca.dk/cvr">32558011</identifier></entity><period><startDate>2023-01-01</startDate><endDate>2023-12-31</endDate></period><scenario><xbrldi:explicitMember dimension="e:ClassesOfEquityDimension">e:RetainedEarningsMember</xbrldi:explicitMember></scenario></context><!--Overfort res forrige EKultimo--><context id="c500"><entity><identifier scheme="http://www.dcca.dk/cvr">32558011</identifier></entity><period><instant>2023-12-31</instant></period><scenario><xbrldi:explicitMember dimension="e:ClassesOfEquityDimension">e:RetainedEarningsMember</xbrldi:explicitMember></scenario></context><!--DKK enere--><unit id="u5"><measure>iso4217:DKK</measure></unit><!--Antal--><unit id="u7"><measure>xbrli:pure</measure></unit></xbrl>
